Glucocorticoid Resistance: Is It a Requisite for Increased Cytokine Production in Depression? A Systematic Review and Meta-Analysis
Open accessThe DOI matches its Crossref record; 82 of the 82 references it cites were found in a registry or an index; none of the 62 sources its claims cite is checked for support yet.
Abstract
Glucocorticoid resistance – reduced function of the glucocorticoid receptor (GR) – is seen in many depressed patients. It is argued that this resistance to glucocorticoids leads to failure of normal feedback regulation on the immune system. High levels of pro-inflammatory cytokines result. We sought to identify evidence supporting or refuting a link between glucocorticoid resistance and immune dysregulation in depression, and to summarize retrieved evidence in aggregate form. Methods: We systematically reviewed and meta-analysed studies that examined cytokine levels in depressed patients compared with controls and that also reported a measure of glucocorticoid resistance. These measures included plasma cortisol, the dexamethasone suppression test (DST), GR expression levels and the results of in vitro assays of GR function. We conducted four separate meta-analyses to test for moderating effects of glucocorticoid resistance on cytokine production in depression. After sub-grouping 32 studies by the ratio of cortisol levels in patients compared with controls, we observed a trend for increasing glucocorticoid resistance (i.e., the most hypercortisolemic patients) to be associated with increased production of IL-6 [d = 0.94; 95% CI (0.29, 1.59)] and TNF-α [d = 0.46; 95% CI (0.12, 0.79)]. We stratified 9 studies that reported DST results by relative glucocorticoid resistance between patients and controls, identifying a trend for higher glucocorticoid resistance in patients, compared with controls, to be associated with higher cytokine production in patients (170 patients and 187 controls). This was particularly evident when studies were sub-grouped by source of cytokine – plasma [d = 1.04; 95% CI (0.57, 1.50)] versus in vitro [d = 0.24; 95% CI (-0.20, 0.67)]. Stratifying the 4 studies (147 patients and 118 controls) that used in vitro assays of GR function or GR expression to quantify glucocorticoid resistance revealed variable contributions to cytokine production in patients compared with controls [overall effect size d = 1.35; 95% CI (0.53, 2.18)]. Our work provides some support for a model conceptualizing glucocorticoid resistance as a requisite for increased inflammation in depression. The limited number of studies identified highlights the need for purpose-designed investigations that directly examine the relationship between glucocorticoid resistance and cytokine production in depression.
Overview
CoChat Summary
TL;DR
This systematic review and meta-analysis found only modest support for glucocorticoid resistance as a requisite for increased cytokine production in depression, with the largest effects when resistance was indexed by plasma/salivary cortisol. Across 32 cortisol studies, IL-6 and TNF-α were higher in depressed patients, but combined DST/in vitro/GR-expression analyses showed no evident positive correlation between glucocorticoid resistance and inflammation.
Key findings
- In 32 studies grouped by patient:control plasma cortisol ratio, hypercortisolemic patients showed a larger IL-6 effect size (d = 0.94; 95% CI 0.29–1.59) than eucortisolemic patients (d = 0.52; 95% CI 0.26–0.77), though the difference was not statistically significant; overall IL-6 effect was d = 0.61 (95% CI 0.36–0.85) based on 1,850 patients and 1,232 controls.
- TNF-α overall effect was d = 0.40 (95% CI 0.12–0.68); hypercortisolemic patients showed d = 0.46 (95% CI 0.12–0.79) versus eucortisolemic d = 0.39 (95% CI −0.19 to 0.98), a non-significant trend, with insufficient hypocortisolemic studies for comparison.
- Nine DST/endocrine suppression studies (170 patients, 187 controls) showed overall higher cytokine levels in patients (d = 0.81; 95% CI 0.39–1.23); plasma cytokine studies showed d = 1.04 (95% CI 0.57–1.50) versus in vitro stimulated studies d = 0.24 (95% CI −0.20 to 0.67), a significant subgroup difference (p = 0.01).
- Four in vitro GR function/GR expression studies (147 patients, 118 controls) had an overall effect d = 1.35 (95% CI 0.53–2.18) but no obvious positive association between glucocorticoid resistance and cytokine production; combining these with DST studies (302 patients, 277 controls) gave d = 1.02 (95% CI 0.55–1.49) with no evident positive correlation between glucocorticoid resistance and inflammation.
Methods
- PRISMA systematic review and meta-analysis using three complementary searches of MEDLINE, EMBASE, PsycInfo, and the Cochrane Database from origin to October 31, 2018, for adult (>17 years) depressed patients and controls diagnosed by standardized clinical/diagnostic interview, with both a glucocorticoid-resistance measure and cytokine levels; exclusions included bipolar/psychotic/substance use disorders, acute infection within 2 weeks, and BMI >30, with allowances for chronic conditions or immune-modulating therapies if <10% or matched.
- Glucocorticoid resistance was assessed by relative plasma/salivary cortisol ratio (patient:control), DST or other endocrine suppression test, in vitro GR function, and GR expression; data were extracted as means/SDs or estimated from medians/ranges using the Wan method, and a “glucocorticoid resistance index” was calculated for DST/endocrine and in vitro/GR-expression studies.
- Random-effects meta-analyses in RevMan5 used Cohen’s d; cytokines were meta-analyzed only if reported by five or more studies; subgroup/moderator analyses examined cortisol ratio, DST/endocrine suppression, in vitro/GR expression, and combined data, with heterogeneity assessed by τ² and I², sensitivity analyses, and funnel plots.
Limitations
- Stated: the small number of study subjects and studies limited precision of effect-size estimates; included studies were cross-sectional and not purpose-designed to test the relationship; heterogeneity was high; the authors call for large studies with multiple objective measures of glucocorticoid resistance and medication-free patients.
- Stated measurement limitations: serum cortisol is not always elevated in depression and diurnal timing varied (94% of studies measured morning cortisol, generally 0700–1100, not all in the post-awakening hour); the DST measures peripheral resistance only and cut-offs varied; in vitro/GR-expression findings may not translate to the CNS; the glucocorticoid resistance index uses relative differences, so small absolute differences can appear large.
- Evident from the text: many patients were taking antidepressants (69% of cortisol studies, 7/9 DST studies, and 40–100% of in vitro/GR-expression studies), some studies had data gaps, and heterogeneity remained high in several pooled analyses (e.g., I² = 84% for IL-6 and 87% for the in vitro/GR-expression analysis), which may limit certainty.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures






Verification
Claims the paper makes
0 Valid · 2 Not valid · 56 Not checked · 141 Own results and interpretations
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“and tumour necrosis factor (TNF)-α [d = 0.46; 95% CI (0.12, 0.79)].”
§ Glucocorticoid Resistance: Is It a Requisite for Increased Cytokine Production in Depression? A Systematic Review and Meta-Analysis > Abstract
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Rests on an assumption not shown here.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Stratifying the four studies (147 patients and 118 controls) that used in vitro assays of GR function or GR expression to quantify glucocorticoid resistance revealed variable contributions to cytokine production in patients compared with controls (overall effect size: d = 1.35; 95% CI 0.53–2.18).”
§ Glucocorticoid Resistance: Is It a Requisite for Increased Cytokine Production in Depression? A Systematic Review and Meta-Analysis > Abstract
plainstates an associationn = 147- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Irrespective of glucocorticoid resistance levels, patient levels of CRP (d = 0.23; 95% CI, −0.01 to 0.46), IFN-γ (d = 0.22; 95% CI, −0.02 to 0.47), IL-1β (d = 0.18; 95% CI, −0.24 to 0.61), and IL-2 (d = −0.12; 95% CI, −1.04 to 0.80) were all not significantly different from control.”
§ Glucocorticoid Resistance: Is It a Requisite for Increased Cytokine Production in Depression? A Systematic Review and Meta-Analysis > Results > i) Glucocorticoid Resistance as Assessed by Relative Plasma Cortisol Levels Between Depressed Patients and Controls
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Overall effect size, based on 147 patients and 118 controls, was significantly different from 0 (d = 1.35; 95% CI, 0.53–2.18; p = 0.001; Figure 5 ).”
§ Glucocorticoid Resistance: Is It a Requisite for Increased Cytokine Production in Depression? A Systematic Review and Meta-Analysis > Results > iii) Glucocorticoid Resistance Measured in In Vitro or from GR Expression Levels in Patients and Controls
plainn = 147- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Examination of regression residuals did not support the existence of a significant trend, however (data not shown).”
§ Glucocorticoid Resistance: Is It a Requisite for Increased Cytokine Production in Depression? A Systematic Review and Meta-Analysis > Results > ii) Glucocorticoid Resistance Measured by DST or Other Endocrine Suppression Test in Patients and Controls
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
78 more claims
Create a free account to see all 199 claims and to verify the 62 references still open.
- Probably not a substantial claim. 89
- It may state two separate claims as one. 45
- The quote only partly states this claim. 2
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated major: it would touch a result — a value a result rests on, reported and recomputed p-values on opposite sides of the significance level, two passages that conflict with no sign which is right, or a cited work retracted before this paper was published.
In the paper
§ Glucocorticoid Resistance: Is It a Requisite for Increased Cytokine Production in Depression? A Systematic Review and Meta-Analysis > Results > iii) Glucocorticoid Resistance Measured in In Vitro or from GR Expression Levels in Patients and Controls
“77 +/− 7 (SEM) % | 56 +/− 13 (SEM) % | 0.25”
§ Glucocorticoid Resistance: Is It a Requisite for Increased Cytokine Production in Depression? A Systematic Review and Meta-Analysis > Methods > Meta-Analysis
“([1−proportion of basalcontrol]−[1−proportion of basalpatients])/([1−proportion of basalcontrol])”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Glucocorticoid Resistance: Is It a Requisite for Increased Cytokine Production in Depression? A Systematic Review and Meta-Analysis > Results > iii) Glucocorticoid Resistance Measured in In Vitro or from GR Expression Levels in Patients and Controls
“IL-6; plasma | 1025 +/− 175 (SEM) pg/ml | 875 +/− 150 (SEM) pg/ml”
§ Glucocorticoid Resistance: Is It a Requisite for Increased Cytokine Production in Depression? A Systematic Review and Meta-Analysis > Results > i) Glucocorticoid Resistance as Assessed by Relative Plasma Cortisol Levels Between Depressed Patients and Controls
“Plasma—3.0 +/− 0.29 (SEM) pg/ml; whole blood stimulated—1,025 +/− 175 (SEM) pg/ml | Plasma—2.4 +/− 0.1 (SEM) pg/ml; whole blood stimulated—875 +/− 150 (SEM) pg/ml”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
“9.7 +/− 4.5 (SEM) µg/dL | 9.3 +/− 3.7 (SEM) µg/dL | 0.96”
§ Glucocorticoid Resistance: Is It a Requisite for Increased Cytokine Production in Depression? A Systematic Review and Meta-Analysis > Results > i) Glucocorticoid Resistance as Assessed by Relative Plasma Cortisol Levels Between Depressed Patients and Controls
Reported 0.96 · recomputed 1.043011
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Glucocorticoid Resistance: Is It a Requisite for Increased Cytokine Production in Depression? A Systematic Review and Meta-Analysis > Methods > Meta-Analysis
“This measure of relative difference in glucocorticoid resistance varies between −1 (all controls glucocorticoid resistant and none of patients) and 1 (all patients glucocorticoid resistant and none of controls).”
§ Glucocorticoid Resistance: Is It a Requisite for Increased Cytokine Production in Depression? A Systematic Review and Meta-Analysis > Methods > Meta-Analysis
“(proportion of suppressorscontrol−proportion of suppressorspatients)/(proportion of suppressorscontrol)”
Citations
Cites
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: the PRISMA statement
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & for the PRISMA Group (2009) · BMJ · doi:10.1136/bmj.b2535 · Cited by 83,823
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & The PRISMA Group (2009) · PLoS Medicine · doi:10.1371/journal.pmed.1000097 · Cited by 64,042
Wang, G., Ma, R., Qiao, G., Wada, K., Aizawa, Y., & Satoh, T. (2015) · Integrative Medicine International · doi:10.1159/000368408 · Cited by 18,657
Wan, X., Wang, W., Liu, J., & Tong, T. (2014) · BMC Medical Research Methodology · doi:10.1186/1471-2288-14-135 · Cited by 11,735 · cited 1×
“We estimated mean and standard deviations from reported medians, data ranges, and sample sizes using the method of Wan (15).”
MethodFries, E., Hesse, J., Hellhammer, J., & Hellhammer, D. H. (2005) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2005.04.006 · Cited by 1,204 · cited 1×
“Work in the elderly suggests that frailty drives exhaustion of the HPA axis in depression, possibly leading to hypocortisolemia (59, 61, 62) whereas chronic overstimulation of the HPA axis in other age groups can cause longterm hypocortisolemia (61, 63).”
BackgroundGlucocorticoid receptors in major depression: relevance to pathophysiology and treatment
Pariante, C. M., & Miller, A. H. (2001) · Biological Psychiatry · doi:10.1016/s0006-3223(00)01088-x · Cited by 1,147
Self-citationMcEwen, B. S., Biron, C. A., Brunson, K. W., Bulloch, K., Chambers, W. H., Dhabhar, F. S., Goldfarb, R. H., Kitson, R. P., Miller, A. H., Spencer, R. L., et al. (1997) · Brain Research Reviews · doi:10.1016/s0165-0173(96)00012-4 · Cited by 837
Silverman, M. N., & Sternberg, E. M. (2012) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2012.06633.x · Cited by 731
Lamers, F., Vogelzangs, N., Merikangas, K. R., de Jonge, P., Beekman, A. T. F., & Penninx, B. W. J. H. (2013) · Molecular Psychiatry · doi:10.1038/mp.2012.144 · Cited by 691
Glucocorticoids, cytokines and brain abnormalities in depression
Zunszain, P. A., Anacker, C., Cattaneo, A., Carvalho, L. A., & Pariante, C. M. (2011) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2010.04.011 · Cited by 554
Self-citation
Research works printed but not linked: 1
- 2014, Review Manager (RevMan) [Computer program]
Cited by
Social Determinants of Cardiovascular Disease
Powell-Wiley, T. M., Baumer, Y., Baah, F. O., Baez, A. S., Farmer, N., Mahlobo, C. T., Pita, M. A., Potharaju, K. A., Tamura, K., & Wallen, G. R. (2022) · Circulation Research · doi:10.1161/circresaha.121.319811 · Cited by 844
Molecular pathways of major depressive disorder converge on the synapse
Fries, G. R., Saldana, V. A., Finnstein, J., & Rein, T. (2023) · Molecular Psychiatry · doi:10.1038/s41380-022-01806-1 · Cited by 504
“Glucocorticoid resistance, as seen in many MDD patients, has also been previously associated with increased inflammatory markers, supporting the hypothesis of a tight cross-talk between stress and inflammation in the disorder [220].”
ResultImmune targets for therapeutic development in depression: towards precision medicine
Drevets, W. C., Wittenberg, G. M., Bullmore, E. T., & Manji, H. K. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00368-1 · Cited by 348
The HPA axis dysregulation in severe mental illness: Can we shift the blame to gut microbiota?
Misiak, B., Łoniewski, I., Marlicz, W., Frydecka, D., Szulc, A., Rudzki, L., & Samochowiec, J. (2020) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2020.109951 · Cited by 343
The immunology of stress and the impact of inflammation on the brain and behaviour
Ravi, M., Miller, A. H., & Michopoulos, V. (2021) · BJPsych Advances · doi:10.1192/bja.2020.82 · Cited by 147
The interplay of hypoxic and mental stress: Implications for anxiety and depressive disorders
Burtscher, J., Niedermeier, M., Hüfner, K., van den Burg, E. H., Kopp, M., Stoop, R., Burtscher, M., Gatterer, H., & Millet, G. P. (2022) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2022.104718 · Cited by 136
Childhood trauma, HPA axis activity and antidepressant response in patients with depression
Nikkheslat, N., McLaughlin, A. P., Hastings, C., Zajkowska, Z., Nettis, M. A., Mariani, N., Enache, D., Lombardo, G., Pointon, L., Cowen, P. J., et al. (2020) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2019.11.024 · Cited by 124
Self-citationCattaneo, A., Ferrari, C., Turner, L., Mariani, N., Enache, D., Hastings, C., Kose, M., Lombardo, G., McLaughlin, A. P., Nettis, M. A., et al. (2020) · Translational Psychiatry · doi:10.1038/s41398-020-00874-7 · Cited by 115
Self-citationThe Microbiota-Gut-Immune-Glia (MGIG) Axis in Major Depression
Rudzki, L., & Maes, M. (2020) · Molecular Neurobiology · doi:10.1007/s12035-020-01961-y · Cited by 111
Skorobogatov, K., De Picker, L., Verkerk, R., Coppens, V., Leboyer, M., Müller, N., & Morrens, M. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.716980 · Cited by 107
Sarno, E., Moeser, A. J., & Robison, A. J. (2021) · Advances in pharmacology · doi:10.1016/bs.apha.2021.03.004 · Cited by 91
Amasi-Hartoonian, N., Sforzini, L., Cattaneo, A., & Pariante, C. M. (2022) · Current Opinion in Endocrine and Metabolic Research · doi:10.1016/j.coemr.2022.100356 · Cited by 89
Self-citationEnhanced antidepressant effects of BDNF-quercetin alginate nanogels for depression therapy
Xu, D. W., Gao, L., Song, X., Dong, Q.-W., Chen, Y., Cui, Y., & Wang, Q. (2023) · Journal of Nanobiotechnology · doi:10.1186/s12951-023-02150-4 · Cited by 76
Neuroinflammation and neuroprogression in depression: Effects of alternative drug treatments
Richardson, B., MacPherson, A., & Bambico, F. R. (2022) · Brain Behavior & Immunity - Health · doi:10.1016/j.bbih.2022.100554 · Cited by 66
Brain-immune crosstalk in the treatment of major depressive disorder
Branchi, I., Poggini, S., Capuron, L., Benedetti, F., Poletti, S., Tamouza, R., Drexhage, H. A., Penninx, B. W. J. H., & Pariante, C. M. (2021) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2020.11.016 · Cited by 64
Self-citationHigher Baseline Interleukin-1β and TNF-α Hamper Antidepressant Response in Major Depressive Disorder
Benedetti, F., Poletti, S., Vai, B., Mazza, M. G., Lorenzi, C., Brioschi, S., Aggio, V., Branchi, I., Colombo, C., Furlan, R., et al. (2021) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2020.11.009 · Cited by 62
Horowitz, M. A., Cattaneo, A., Cattane, N., Lopizzo, N., Tojo, L. M., Bakunina, N., Musaelyan, K., Borsini, A., Zunszain, P. A., & Pariante, C. M. (2020) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2020.03.012 · Cited by 62
Self-citationStress circuitry: mechanisms behind nervous and immune system communication that influence behavior
Tong, R. L., Kahn, U. N., Grafe, L. A., Hitti, F. L., Fried, N. T., & Corbett, B. F. (2023) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2023.1240783 · Cited by 53
Endocrine and immune effects of non-convulsive neurostimulation in depression: A systematic review
Perrin, A. J., & Pariante, C. M. (2020) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2020.02.016 · Cited by 53
Self-citationBiomarkers Common for Inflammatory Periodontal Disease and Depression: A Systematic Review
Neupane, S. P., Virtej, A., Myhren, L. E., & Bull, V. H. (2022) · Brain, Behavior, & Immunity - Health · doi:10.1016/j.bbih.2022.100450 · Cited by 52
Low glucocorticoids in stress-related disorders: the role of inflammation
Sarapultsev, A., Sarapultsev, P., Dremencov, E., Komelkova, M. V., Tseilikman, O. B., & Цейликман, В. Э. (2020) · Stress · doi:10.1080/10253890.2020.1766020 · Cited by 50
Hage, Z., Madeira, M. M., Koliatsis, D., & Tsirka, S. E. (2024) · BMC Immunology · doi:10.1186/s12865-024-00653-9 · Cited by 50
Dattilo, V., Amato, R., Perrotti, N., & Gennarelli, M. (2020) · Frontiers in Genetics · doi:10.3389/fgene.2020.00826 · Cited by 49
“This results in a reduction in BDNF brain levels that leads to apoptosis or degeneration of neurons (Jin et al., 2019; Perrin et al., 2019).”
BackgroundThe multiple roles of chronic stress and glucocorticoids in Alzheimer's disease pathogenesis
Burke, M. R., Sotiropoulos, I., & Waites, C. L. (2024) · Trends in Neurosciences · doi:10.1016/j.tins.2024.08.015 · Cited by 46
By what molecular mechanisms do social determinants impact cardiometabolic risk?
Baumer, Y., Pita, M. A., Baez, A. S., Ortiz-Whittingham, L. R., Cintron, M., Rose, R., Gray, V. C., Baah, F. O., & Powell‐Wiley, T. M. (2023) · Clinical Science · doi:10.1042/cs20220304 · Cited by 45
Palma-Gudiel, H., Prather, A. A., Lin, J., Oxendine, J. D., Guintivano, J., Xia, K., Rubinow, D. R., Wolkowitz, O., Epel, E. S., & Zannas, A. S. (2021) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2020.11.027 · Cited by 43
Microbiota–gut–brain axis: Natural antidepressants molecular mechanism
Lu, Y., Yu, X., Wang, Z., Kong, L., Jiang, Z., Shang, R., Zhong, X., Lv, S., Zhang, G., Gao, H., et al. (2024) · Phytomedicine · doi:10.1016/j.phymed.2024.156012 · Cited by 42
McLaughlin, A. P., Nikkheslat, N., Hastings, C. N. M., Nettis, M. A., Kose, M., Worrell, C., Zajkowska, Z., Mariani, N., Enache, D., Lombardo, G., et al. (2021) · Psychological Medicine · doi:10.1017/s0033291721000088 · Cited by 39
Self-citationGodara, M., Silveira, S., Matthäus, H., Heim, C., Voelkle, M., Hecht, M., Binder, E. B., & Singer, T. (2021) · PLOS ONE · doi:10.1371/journal.pone.0256323 · Cited by 38
Th17 Cells, Glucocorticoid Resistance, and Depression
Khantakova, J. N., Mutovina, A., Ayriyants, K. A., & Bondar, N. P. (2023) · Cells · doi:10.3390/cells12232749 · Cited by 38
Chou, P., Lu, M., Tsai, C., Hsieh, W., Lai, H.-C., Shityakov, S., & Su, K. (2020) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2020.06.024 · Cited by 38
Refisch, A., Şen, Z. D., Klassert, T. E., Busch, A., Besteher, B., Danyeli, L. V., Helbing, D. L., Schulze‐Späte, U., Stallmach, A., Bauer, M. W., et al. (2023) · Neuropharmacology · doi:10.1016/j.neuropharm.2023.109568 · Cited by 38
Annual Research Review: Social relationships and the immune system during development
Robles, T. F. (2020) · Journal of Child Psychology and Psychiatry · doi:10.1111/jcpp.13350 · Cited by 37
Mitochondrial respiratory capacity modulates LPS-induced inflammatory signatures in human blood
Karan, K. R., Trumpff, C., McGill, M. A., Thomas, J. E., Sturm, G., Lauriola, V., Sloan, R. P., Rohleder, N., Kaufman, B. A., Marsland, A. L., et al. (2020) · Brain Behavior & Immunity - Health · doi:10.1016/j.bbih.2020.100080 · Cited by 35
Neuroimmune Mechanisms and Sex/Gender-Dependent Effects in the Pathophysiology of Mental Disorders
Kokkosis, A. G., & Tsirka, S. E. (2020) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.120.266163 · Cited by 34
Statins: Neurobiological underpinnings and mechanisms in mood disorders
Walker, A. J., Kim, Y., Borissiouk, I., Rehder, R., Dodd, S., Morris, G., Nierenberg, A. A., Maes, M., Fernandes, B. S., Dean, O. M., et al. (2021) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2021.07.012 · Cited by 33
Depression and the Glutamate/GABA-Glutamine Cycle
Mamelak, M. (2024) · Current Neuropharmacology · doi:10.2174/1570159x22666240815120244 · Cited by 32
How inflammation influences psychiatric disease
Ferat-Osorio, E. A., Maldonado-García, J. L., & Pavón, L. (2024) · World Journal of Psychiatry · doi:10.5498/wjp.v14.i3.342 · Cited by 31
Nold, V., Richter, N., Hengerer, B., Kolassa, I., & Allers, K. A. (2020) · European Journal of Neuroscience · doi:10.1111/ejn.14999 · Cited by 31
Chiang, T.-I., Hung, Y.-Y., Wu, M., Huang, Y., & Kang, H. (2021) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2021.04.021 · Cited by 31
Su, W., Hu, T., & Jiang, C. (2023) · Current Neuropharmacology · doi:10.2174/1570159x21666230809112028 · Cited by 29
Investigating the Convergent Mechanisms between Major Depressive Disorder and Parkinson’s Disease
Tran, A. A., Smet, M. D., Grant, G. D., Khoo, T. K., & Pountney, D. L. (2020) · Complex Psychiatry · doi:10.1159/000512657 · Cited by 29
Srinivasan, M., & Walker, C. L. (2022) · ASN NEURO · doi:10.1177/17590914221120190 · Cited by 27
Prenatal diurnal cortisol: Normative patterns and associations with affective symptoms and stress
Murphy, H. R., Gu, Y., Wu, Q., Brunner, J., Panisch, L. S., Best, M., Arnold, M. S., Duberstein, Z. T., Putzig, J., Carnahan, J. A., et al. (2022) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2022.105856 · Cited by 25
Bose, M. M., Govindula, A., Nampoothiri, M., Arora, D. S., & Mudgal, J. (2025) · Pharmacological Reports · doi:10.1007/s43440-025-00806-6 · Cited by 19
The Microbiota-gut-immune-glia (MGIG) Axis in Major DepressionPreprint
Rudzki, L., & Maes, M. H. J. (2020) · Preprints.org · doi:10.20944/preprints202002.0084.v1 · Cited by 18
Longitudinal hair cortisol in bipolar disorder and a mechanism based on HPA dynamics
Milo, T., Maimon, L., Cohen, B., Haran, D., Segman, D., Danon, T., Bren, A., Mayo, A., Rappaport, G. C., McInnis, M. G., et al. (2024) · iScience · doi:10.1016/j.isci.2024.109234 · Cited by 17
Liu, Y., McGarry, S. V., Cruickshank, D., & Jensen, G. S. (2023) · PLoS ONE · doi:10.1371/journal.pone.0291254 · Cited by 17
Bodnaruc, A. M., Roberge, M., Giroux, I., & Aguer, C. (2024) · Endocrines · doi:10.3390/endocrines5040035 · Cited by 16
Chapter 4. Psychoneuroendocrinology
Sforzini, L., Weston, F. I., & Pariante, C. M. (2024) · American Psychiatric Association Publishing eBooks · doi:10.1176/appi.books.9781615375523.as04 · Cited by 16
Self-citationLee, S., Lee, K. H., Park, K. M., Park, S. J., Kim, W. J., Lee, J., Kronbichler, A., Smith, L., Solmi, M., Stubbs, B., et al. (2021) · Psychological Medicine · doi:10.1017/s0033291721003767 · Cited by 15
Differential effect of interferon-alpha treatment on AEA and 2-AG levels
Zajkowska, Z., Borsini, A., Nikkheslat, N., Russell, A., Romano, G. F., Tomassi, S., Hepgul, N., Forton, D. M., Agarwal, K., Hotopf, M. H., et al. (2020) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2020.08.024 · Cited by 14
Self-citationThe Constrained Disorder Principle: Beyond Biological Allostasis
Adar, O., Shakargy, J. D., & Ilan, Y. (2025) · Biology · doi:10.3390/biology14040339 · Cited by 13
Parallel Pathways, Divergent Outcomes: Adipose Tissue–Neural Crosstalk in Depression and Obesity
Prodaniuc, A., Amălinei, C., Căruntu, I.-D., Riscanu, L., & Grigoraş, A. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14238307 · Cited by 13
dos Santos, B. M., Pereira, G. C., Piton, E., Fialho, M. F. P., Becker, G., Carlotto, M. D. S., Camargo, L. F. M., Ramanzini, L. G., Oliveira, S. M., Trevisan, G., et al. (2022) · Behavioural Brain Research · doi:10.1016/j.bbr.2022.113815 · Cited by 13
Cattaneo, A., Ferrari, C., Turner, L., Mariani, N., Enache, D., Hastings, C. N. M., Kose, M., Lombardo, G., McLaughlin, A. P., Nettis, M. A., et al. (2020) · Translational Psychiatry · doi:10.1038/s41398-020-01044-5 · Cited by 13
Self-citationExperimental Therapeutics in Treatment-Resistant Major Depressive Disorder
Kaur, M., & Sanches, M. (2021) · Journal of Experimental Pharmacology · doi:10.2147/jep.s259302 · Cited by 12
Allostatic Load and Metabolic Syndrome in Depressed Patients: A Cross‐Sectional Analysis
Osei, F., Wippert, P., & Block, A. (2024) · Depression and Anxiety · doi:10.1155/2024/1355340 · Cited by 12
Cavalleri, L., Dassieni, I., Marcotto, G. S., Zoli, M., Pich, E. M., & Collo, G. (2024) · Neuroscience Applied · doi:10.1016/j.nsa.2024.104049 · Cited by 11
Repairing blood-CNS barriers: Future therapeutic approaches for neuropsychiatric disorders
Bicker, J., Alves, G., Fonseca, C., Falcão, A. C., & Fortuna, A. C. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2020.105226 · Cited by 11
Corwin, E. J., Dunlop, A. L., Fernandes, J., Li, S., Pearce, B. D., & Jones, D. P. (2020) · Comprehensive Psychoneuroendocrinology · doi:10.1016/j.cpnec.2020.100001 · Cited by 11
Putative Mental, Physical, and Social Mechanisms of Hormonal Influences on Postpartum Sexuality
Clephane, K., & Lorenz, T. K. (2021) · Current Sexual Health Reports · doi:10.1007/s11930-021-00321-8 · Cited by 10
Rajkumar, R. P. (2024) · Brain Sciences · doi:10.3390/brainsci14060543 · Cited by 9
Hong, Y., Sourander, C., Hackl, B., Patton, J., John, J., Paatero, I., & Coffey, E. T. (2024) · Scientific Reports · doi:10.1038/s41598-024-61337-3 · Cited by 8
Wang, Y., Qin, J., Dong, L., He, C., Zhang, D., Wu, X., Li, T., Yue, H., Mu, L., Wang, Q., et al. (2023) · Molecular Immunology · doi:10.1016/j.molimm.2023.09.002 · Cited by 8
Hough, C. M., Kruse, J. L., Espinoza, R. T., Brooks, J. O., Congdon, E. L., Norris, V., Craske, M. G., & Narr, K. L. (2024) · Brain Behavior & Immunity - Health · doi:10.1016/j.bbih.2024.100925 · Cited by 7
Hong, S. (2020) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2020.04.076 · Cited by 7
Amini, M., Motevaseli, E., Zahmatkesh, M., Yousefi, Z., Esmaeil-Jamaat, E., Hassanzadeh, G., & Mokhtari, T. (2026) · Molecular Neurobiology · doi:10.1007/s12035-025-05656-0 · Cited by 6
Schrier, M. S., Smirnova, M. I., Nemeth, D. P., Deth, R. C., & Quan, N. (2025) · Journal of Inflammation Research · doi:10.2147/jir.s501652 · Cited by 6
Behzad, A., Feldmann-Schulz, C., Lenz, B., Clarkson, L., Ludwig, C., Luttenberger, K., Völkl, S., Kornhuber, J., Mühle, C., & von Zimmermann, C. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13092494 · Cited by 6
Use of Extracellular Monomeric Ubiquitin as a Therapeutic Option for Major Depressive Disorder
Maldonado-García, J. L., García-Mena, L. H., Cabrera, D. M., Pérez‐Sánchez, G., Becerril‐Villanueva, E., Álvarez-Herrera, S., Homberg, T. A., Vallejo‐Castillo, L., Pérez‐Tapia, S. M., Moreno-Lafont, M. C., et al. (2024) · Pharmaceuticals · doi:10.3390/ph17070841 · Cited by 5
Mariani, N., McLaughlin, A. P., Lambert, E. R., Kose, M., Nikkheslat, N., Patsalos, O., Bogdanova, A., Chamseddine, G., Panagiotopoulos, S., Chang, A., et al. (2023) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2023.106387 · Cited by 5
Navigating glucocorticoid resistance: From GR isoforms to nuclear condensates
Wang, C., Zhong, Y., Tang, M., He, X., Xu, S., & Zhang, J. (2025) · Cell investigation. · doi:10.1016/j.clnves.2025.100059 · Cited by 4
Stress and the risk of Alzheimer dementia: Can deconstructed engrams be rebuilt?
Jeanneteau, F. D. (2023) · Journal of Neuroendocrinology · doi:10.1111/jne.13235 · Cited by 4
Fu, Y., Liu, S., Dong, Y., Gan, Y., Guo, X., Liu, H., Xu, Q., Yuan, R., Ning, A., Hong, W., et al. (2022) · Psychopharmacology · doi:10.1007/s00213-022-06302-6 · Cited by 4
Kirkpatrick, M., Priestley, K., Bind, R. H., Rebecchini, L., Borsini, A., Estevao, C., Hazelgrove, K. M., Laijawala, R., Alford, S., Woods, A. J., et al. (2026) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2026.106600 · Cited by 3
Self-citationUnraveling the molecular pathways linking polystyrene exposure and depression
Murthy, M. K. (2025) · Environmental Science and Pollution Research · doi:10.1007/s11356-025-37184-8 · Cited by 3
Murata, S., Murphy, M. L. M., Khanna, R., Hoppensteadt, D., Fareed, J., & Halaris, A. E. (2021) · Journal of Affective Disorders Reports · doi:10.1016/j.jadr.2021.100117 · Cited by 3
Weston, F. I., Sforzini, L., Cattaneo, A., & Pariante, C. M. (2023) · Masterclass in neuroendocrinology · doi:10.1007/978-3-031-21358-8_6 · Cited by 2
Self-citationA history of social adversity is associated with adolescents’ ex vivo inflammatory response
Michels, N., McDade, T. W., Krause, K. C., Miller, A. A., & Giletta, M. (2025) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2025.107620 · Cited by 2
Pavón, L., Cabrera, D. M., Pérez‐Sánchez, G., Becerril-Villanueva, L. E., Álvarez-Herrera, S., Vallejo‐Castillo, L., García-Mena, L. H., & Maldonado-García, J. L. (2024) · Integrated science · doi:10.1007/978-3-031-72079-6_6 · Cited by 1
Palladini, M., Azzalin, A. A., Bessi, M., LORENZO, R. D., Rovere, P. Q., Benedetti, F., & Mazza, M. G. (2025) · Journal of Neuroimmune Pharmacology · doi:10.1007/s11481-025-10247-w · Cited by 1
From memory disorders to the development of depression: A system approach
Grigoryan, G. A. (2025) · Biosystems · doi:10.1016/j.biosystems.2025.105440 · Cited by 1
Pan, J., Liu, J., Fan, Q., Gao, S., Yu, L., & Zhang, L. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1606445 · Cited by 1
Pilatti, F., Philippsen, M., Bertollo, A. G., WEBLER, C. P., Bordignon, A. K., & Ignácio, Z. M. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1801474 · Cited by 1
Laurent, H. K., Goodman, S. H., Granger, D. A., & Backer, P. M. (2025) · Brain Behavior & Immunity - Health · doi:10.1016/j.bbih.2025.101145 · Cited by 1
Glucocorticoid signalling dysregulation and immune cell adaptation in Anorexia Nervosa
Mottarlini, F., Dalt, L. D., Parolaro, S., Baragetti, A., Rizzi, B., Taddini, S., Cigognini, A. C., Vairano, F., Bertelli, S., D’Agostino, A., et al. (2026) · Molecular Psychiatry · doi:10.1038/s41380-026-03756-4 · Cited by 1
Amro, C., Chang, A. E., Ewing, J. N., Lemdani, M. S., Gala, Z. S., Broach, R. B., Serletti, J. M., & Azoury, S. C. (2025) · Plastic & Reconstructive Surgery · doi:10.1097/prs.0000000000012410 · Cited by 1
López‐Morales, H., López, M., Sosa, J. M., Zabaletta, V., Berardino, B. G., Cánepa, E. T., & Urquijo, S. (2026) · Journal of Affective Disorders · doi:10.1016/j.jad.2026.121687 · Cited by 1
Salman, R., Ritter, P., Ryabushkina, Y. A., Khantakova, J. N., & Bondar, N. (2025) · Behavioural Brain Research · doi:10.1016/j.bbr.2025.116000 · Cited by 1
Stress Influences on Neuroendocrine and Immune System
Aas, M. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-819641-0.00101-8
Gardhouse, K. (2020) · TSpace (University of Toronto)
Associação entre eventos de vida, depressão e doença periodontal: revisão de literatura
Santos, L. G., Neto, A. A. S., Pereira, A. D. L., Cordeiro, W. A., & Cunha, P. D. O. (2023) · Brazilian Journal of Health Review · doi:10.34119/bjhrv6n6-056
Wilson, K. L., Boettner, B. L., Browning, C. R., Ford, J. L., & Way, B. M. (2025) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2025.107722
Antidepresivi i COVID-19: prikaz slučaja i pregled literature
Dabetic, M., Jovicic, M. J., Dabetić, U., & Latas, M. B. (2022) · Engrami · doi:10.5937/engrami44-39941
Antidepressants and COVID-19: A case report and review of the literature
Dabetic, M., Nešić, M., Dabetić, U., & Latas, M. B. (2022) · Engrami · doi:10.5937/engrami43-39941
Xu, D., Gao, L.-N., Song, X.-J., Dong, Q.-W., Chen, Y.-B., Cui, Y.-L., & Wang, Q. (2023) · Figshare · doi:10.6084/m9.figshare.24329746
Joseph, C. L. M., Greenlee, A. J., Sitarik, A. R., Perkins, D. W., Miree, C. A., & Wegienka, G. (2025) · Medical Hypotheses · doi:10.1016/j.mehy.2025.111713
Hough, C. M. (2023) · eScholarship (California Digital Library)
Metadata
- Authors
- Perrin, A. J., Horowitz, M. A., Roelofs, J., Zunszain, P. A., & Pariante, C. M.
- Affiliations
- University of British Columbia (CA)
- King's College London (GB)
- Corresponding author
- Perrin, Andrew J.
- Venue
- Frontiers in Psychiatry
- Publisher
- Frontiers Media SA
- Published
- 2019-06-28
- Volume
- 10
- Pages
- 423-423
- ISSN
- 1664-0640 (ISSN-L)
- PMC
- PMC6609575
- OpenAlex
- W2955135686
- Semantic Scholar
- fd07c6b7e05e764d80c7201d82483726cbab6ce1
- Cited by
- 112
- References
- 82
- Citations by year
- 2026: 15 · 2025: 16 · 2024: 18 · 2023: 14 · 2022: 13 · 2021: 12 · 2020: 23 · 2019: 1
- FWCI
- 1.17
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Frontiers in Psychiatry (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Research Portal (King's College London) (publishedVersion, other-oa)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- UCL Discovery (University College London) (submittedVersion)
- Funders
- South London and Maudsley NHS Foundation Trust (MR/L014815/1)
- NIHR Biomedical Research Centre, Royal Marsden NHS Foundation Trust/Institute of Cancer Research
- Royal College of Physicians and Surgeons of Canada
- National Institute for Health and Care Research (NF-SI-0616-10074)
- King's College London
- Medical Research Council (MR/N029488/1, MR/L014815/1, MR/J002739/1)
- Topics
- Life Sciences › Neuroscience › Behavioral Neuroscience › Stress Responses and Cortisol
- Life Sciences › Neuroscience › Biological Psychiatry › Tryptophan and brain disorders
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Keywords
- depression, cytokine production, glucocorticoid receptor, hypercortisolism, dexamethasone suppression test, interleukin-6, TNF-α, immune dysregulation, hypothalamic-pituitary-adrenal axis, inflammatory cytokines, glucocorticoid receptor expression, plasma cortisol, moderating effect
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-11-21, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-11-21 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.